Glenmark Pharmaceuticals Inc., USA has announced the launch of Clindamycin Phosphate Foam 1%, expanding its dermatological treatment portfolio. The newly launched product is both bioequivalent and therapeutically equivalent to Mylan Pharmaceuticals Inc.'s Evoclin® Foam 1%, the reference listed drug.
Market Opportunity and Commercial Impact
Market analysis from IQVIA™ reveals that the Evoclin® Foam 1% market, including brand and therapeutic equivalents, generated approximately $5.8 million in annual sales during the 12-month period ending December 2024. This launch represents a strategic addition to Glenmark's growing generic pharmaceutical offerings in the United States market.
Company Profile and Global Presence
Glenmark Pharmaceuticals Ltd. has established itself as a research-driven global pharmaceutical company with a diverse portfolio spanning Branded, Generics, and OTC segments. The company maintains a particular focus on respiratory, dermatology, and oncology therapeutic areas.
With 11 world-class manufacturing facilities across four continents and operations in more than 80 countries, Glenmark has built a substantial global footprint. The company's market position is notable, ranking among the Top 100 biopharmaceutical companies in Scrip 100's 2023 pharmaceutical sales rankings. Additionally, Generics Bulletin places Glenmark among the Top 50 Generics and biosimilar companies by sales in 2024.
Environmental and Social Commitment
In 2023, Glenmark achieved a significant environmental milestone by receiving approval for their Green House Gas (GHG) emission reduction targets from the Science Based Target initiative (SBTi), becoming only the second pharmaceutical company in India to reach this achievement. The company has also demonstrated strong social responsibility, positively impacting over 3.3 million lives through various CSR initiatives over the past decade.
